Biden Directs FDA, CMS, FTC To Boost Interchangeable Biosimilars, Generics

By Beth Wang / July 9, 2021 at 7:05 PM
President Joe Biden on Friday (July 9) directed FDA, CMS and the Federal Trade Commission to take steps to boost the generics and biosimilars markets in order to increase competition and lower drug prices. Biden specifically asks FDA to clarify and improve the standards for interchangeable biosimilars, work with FTC to curb false and misleading statements about generic and biosimilar products, promptly issue Covered Product Authorizations (CPAs) to help generic drug developers obtain brand drug samples needed to support their...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.